Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

NCT00002118 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00002118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies
Lead sponsor
Hoffmann-La Roche
Phase
Not applicable
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
600
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections